Evidence map›Paper›PMID 37652498›Full record

ArticleIn vivo (Athens, Greece)

Thomas Schneider, Felix Zwicker, Peter Ernst Huber, Jürgen Debus, Henrik Hauswald

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Thomas SchneiderDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Felix ZwickerClinical Cooperation Unit E055, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Peter Ernst HuberClinical Cooperation Unit E055, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jürgen DebusDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Henrik HauswaldDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; hausw@gmx.de.
Heidelberg University · DEGerman Cancer Research Center · DEPraxis für Humangenetik · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo determine the interaction of gemcitabine in chemoradiotherapy with heavy carbon ions in vitro in a mucoepidermoid carcinoma (MEC) cell line. MATERIALS AND

methodsThe human lymphatic MEC metastasis cell line NCI-H292 was used. The cells were treated with photons, carbon ions, and gemcitabine. Survival fractions (SF), apoptosis, and cell cycle progression were analyzed. A paired two-sided t-test was used. Significance was defined as p<0.05.

resultsCell proliferation assays showed a significant reduction in SF for combined photon chemoradiation versus photons only. The linear-quadratic fits of combined therapy with carbon ion dose of 0 to 2.5 Gy led to reductions of mean 15% in SF. The LD

conclusionGemcitabine showed radiosensitizing effects in combination with photons. The combination of gemcitabine and carbon ions had independent additive effects. Carbon ions only had a RBE10 of 3.0, compared to photons only. The combination of gemcitabine, photon, and carbon ions in patients with MEC seems promising and warrants further investigation.

Indexed as

Carcinoma, MucoepidermoidHeavy Ion RadiotherapyCarbonCell Line, TumorChemoradiotherapyDeoxycytidineGemcitabineHumansIonsPhotonsCarbonDeoxycytidineGemcitabineIonscarbon ion beam therapychemoradiationhead and neckin vitroion beam therapyMucoepidermoid carcinomaparticle beam therapyradiotherapy

Identifiers

PMID37652498
PMCPMC10500520
OpenAlexW4386337530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.